Search

Your search keyword '"ADC Therapeutics S.A. -- Forecasts and trends"' showing total 23 results
Start Over Descriptor "ADC Therapeutics S.A. -- Forecasts and trends"
23 results on '"ADC Therapeutics S.A. -- Forecasts and trends"'

1. Waldenstrom Macroglobulinemia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | AbbVie, Cellectar Biosciences, TG Therapeutics, Eli Lilly and Company, Celgene Corp

Subjects
ADC Therapeutics S.A. -- Forecasts and trends, AstraZeneca PLC -- Forecasts and trends, Eli Lilly and Co. -- Forecasts and trends, Celgene Corp. -- Forecasts and trends, Antineoplastic agents -- Reports -- Forecasts and trends, Ofatumumab -- Forecasts and trends -- Reports, B cells -- Growth -- Reports -- Forecasts and trends, Epidemiology -- Forecasts and trends -- Reports, Antimitotic agents -- Reports -- Forecasts and trends, Company growth, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-December 6, 2024-: Waldenstrom Macroglobulinemia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | AbbVie, Cellectar Biosciences, TG Therapeutics, Eli Lilly and Company, Celgene Corp (C)1994-2024 M2 [...]

Published
2024

2. Antibody-Drug Conjugates Market to Grow at 28.4% CAGR from 2024 to 2029

Subjects
ADC Therapeutics S.A. -- Forecasts and trends, Biopharmaceutics -- Reports -- Forecasts and trends, Viral antibodies -- Reports -- Forecasts and trends, Antibodies -- Reports -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

BOSTON: BCC Research LLC has issued the following press release: 'According to the latest BCC Research study, 'The global ADCs market is showing a rapid growth trend, with growth rates [...]

Published
2024

3. Antibody-Drug Conjugates Market to Grow at 28.4% CAGR from 2024 to 2029

Subjects
ADC Therapeutics S.A. -- Forecasts and trends, Biopharmaceutics -- Forecasts and trends, Viral antibodies -- Forecasts and trends, Antibodies -- Forecasts and trends, Industrial research -- Switzerland -- United Kingdom, Pharmaceutical industry -- Forecasts and trends, Research and development, Market trend/market analysis, Business, News, opinion and commentary
Abstract

'With 13 Commercially Available Products Globally and More than 200 in Clinical Trials, ADC Market is Set to Grow Exponentially' BOSTON, Oct. 21, 2024 /PRNewswire/ -- 'According to the latest [...]

Published
2024

4. Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market size is set to grow by USD 2.24 billion from 2024-2028, Growing geriatric population boost the market, Technavio

Subjects
ADC Therapeutics S.A. -- Forecasts and trends, Amgen Inc. -- Forecasts and trends, Bayer AG -- Forecasts and trends, Gilead Sciences Inc. -- Forecasts and trends, AbbVie Inc. -- Forecasts and trends, Bristol-Myers Squibb Co. -- Forecasts and trends, Novartis AG -- Forecasts and trends, Biological products industry -- Forecasts and trends, Patient compliance -- Forecasts and trends, Biotechnology industry -- Forecasts and trends, Lymphomas -- Forecasts and trends, Vincristine -- Forecasts and trends -- Market size, Radiotherapy -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

NEW YORK: Technavio has issued the following news release: The global diffuse large B-cell lymphoma (DLBCL) therapeutics market size is estimated to grow by USD 2.24 billion from 2024-2028, according [...]

Published
2024

5. Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market size is set to grow by USD 2.24 billion from 2024-2028, Growing geriatric population boost the market, Technavio

Subjects
ADC Therapeutics S.A. -- Forecasts and trends, Amgen Inc. -- Forecasts and trends, Bayer AG -- Forecasts and trends, AbbVie Inc. -- Forecasts and trends, Bristol-Myers Squibb Co. -- Forecasts and trends, Biological products industry -- Forecasts and trends, Patient compliance -- Forecasts and trends, Biotechnology industry -- Forecasts and trends, Lymphomas -- Forecasts and trends, Vincristine -- Forecasts and trends -- Market size, Radiotherapy -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Business, News, opinion and commentary
Abstract

NEW YORK, June 27, 2024 /PRNewswire/ -- The global diffuse large B-cell lymphoma (DLBCL) therapeutics market size is estimated to grow by USD 2.24 billion from 2024-2028, according to Technavio. [...]

Published
2024

6. Antibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 - Exclusive Study by The Insight Partners

Subjects
Astellas Pharma Inc. -- Forecasts and trends, ADC Therapeutics S.A. -- Forecasts and trends, Pfizer Inc. -- Forecasts and trends, Insight Partners -- Forecasts and trends, AstraZeneca PLC -- Forecasts and trends, Antineoplastic agents -- Reports -- Forecasts and trends, Biological products -- Reports -- Forecasts and trends, Venture capital companies -- Forecasts and trends, Monoclonal antibodies -- Reports -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Antimitotic agents -- Reports -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries, Business
Abstract

Pune, India, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Antibody drug conjugates (ADC) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody (mAbs) covalently [...]

Published
2023

7. Antibody Drug Conjugates (ADC) Market worth $19.8 billion | MarketsandMarkets

Subjects
ADC Therapeutics S.A. -- Forecasts and trends, Biopharmaceutics -- Statistics, Independent regulatory commissions -- Forecasts and trends -- Statistics, Antineoplastic agents -- Statistics, Monoclonal antibodies -- Statistics -- Forecasts and trends, Pharmaceutical industry -- Statistics -- Forecasts and trends, Antimitotic agents -- Statistics, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

CHICAGO: MarketsandMarkets has issued the following news release: The Antibody Drug Conjugates (ADC) industry represents a cutting-edge and rapidly evolving sector within the field of biopharmaceuticals. ADCs are a class [...]

Published
2023

8. Antibody Drug Conjugates (ADC) Market worth $19.8 billion | MarketsandMarkets

Subjects
ADC Therapeutics S.A. -- Forecasts and trends, Biopharmaceutics -- Statistics, Independent regulatory commissions -- Forecasts and trends -- Statistics, Antineoplastic agents -- Statistics, Monoclonal antibodies -- Statistics -- Forecasts and trends, Pharmaceutical industry -- Statistics -- Forecasts and trends, Antimitotic agents -- Statistics, Market trend/market analysis, Business, News, opinion and commentary
Abstract

CHICAGO, Oct. 5, 2023 /PRNewswire/ -- The Antibody Drug Conjugates (ADC) industry represents a cutting-edge and rapidly evolving sector within the field of biopharmaceuticals. ADCs are a class of targeted [...]

Published
2023

9. Acute Lymphocytic Leukemia Market to Accelerate Substantially by 2032, Assesses DelveInsight | Key Companies in the Market - Beam, Pfizer, Genentech, AbbVie, Fate, Roche, Ascentage, Janssen, Jazz, ADC, Kymera, Syndax, ImmunoGen

Subjects
ADC Therapeutics S.A. -- Forecasts and trends, Genentech Inc. -- Forecasts and trends, Pfizer Inc. -- Forecasts and trends, Beam Therapeutics Inc. -- Forecasts and trends, Oncology, Experimental -- Forecasts and trends, Biological products industry -- Forecasts and trends, Business -- Research, Patient compliance -- Forecasts and trends, Antineoplastic agents -- Forecasts and trends, Biotechnology industry -- Forecasts and trends, Antigens -- Forecasts and trends, Acute lymphocytic leukemia -- Forecasts and trends, Cancer -- Research, Pharmaceutical industry -- Forecasts and trends, Antimitotic agents -- Forecasts and trends, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

LAS VEGAS: DelveInsight Business Research, LLP has issued the following news release:= DelveInsight's Acute Lymphocytic Leukemia Market Insights report includes a comprehensive understanding of current treatment practices, acute lymphocytic leukemia [...]

Published
2023

10. Acute Lymphocytic Leukemia Market to Accelerate Substantially by 2032, Assesses DelveInsight | Key Companies in the Market - Beam, Pfizer, Genentech, AbbVie, Fate, Roche, Ascentage, Janssen, Jazz, ADC, Kymera, Syndax, ImmunoGen

Subjects
ADC Therapeutics S.A. -- Forecasts and trends, Pfizer Inc. -- Forecasts and trends, Oncology Inc. -- Forecasts and trends, Oncology, Experimental -- Forecasts and trends, Biological products industry -- Forecasts and trends, Patient compliance -- Forecasts and trends, Antineoplastic agents -- Forecasts and trends, Antigens -- Forecasts and trends, Acute lymphocytic leukemia -- Forecasts and trends, Cancer -- Research, Pharmaceutical industry -- Forecasts and trends, Antimitotic agents -- Forecasts and trends, Market trend/market analysis, Business, News, opinion and commentary
Abstract

The dynamics of the acute lymphocytic leukemia market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental [...]

Published
2023

11. 50+ Active Companies working to develop 50+ Pipeline Therapies for Relapsed Refractory Acute Myeloid Leukemia R R AML Treatment

Subjects
United States. Food and Drug Administration -- Reports, ADC Therapeutics S.A. -- Forecasts and trends, Therapeutics Inc. -- Forecasts and trends, Diseases -- Relapse, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-March 23, 2023-: 50+ Active Companies working to develop 50+ Pipeline Therapies for Relapsed Refractory Acute Myeloid Leukemia R R AML Treatment (C)1994-2023 M2 COMMUNICATIONS RDATE:22032023 DelveInsight's, 'Relapsed/refractory acute [...]

Published
2023

12. Global Antibody Drug Conjugates (ADC) Markets, 2022-2028: Increasing Cases of Cancer with ADCs Showing to be a Substitute for Conventional Cancer Treatments Like Chemotherapy or Combination Therapy (Updated on September 15, 2022)

Subjects
United States. Food and Drug Administration -- Statistics, ADC Therapeutics S.A. -- Forecasts and trends, Seagen Inc. -- Forecasts and trends, Biopharmaceutics -- Statistics, Biotechnology industry -- Forecasts and trends -- Statistics, Viral antibodies -- Statistics -- Forecasts and trends, Chemotherapy -- Forecasts and trends -- Statistics, Cancer -- Chemotherapy, Antibodies -- Statistics -- Forecasts and trends, Pharmaceutical industry -- Statistics -- Forecasts and trends, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Global Antibody Drug Conjugates Market Size, Share & Industry Trends Analysis Report By Application, By Technology, By Regional Outlook [...]

Published
2022

13. Global Antibody Drug Conjugates (ADC) Market Analysis Report 2022: A $13.8 Billion Market by 2028 - Increased Investments by Key Industry Players

Subjects
United States. Food and Drug Administration -- Statistics -- Reports, ADC Therapeutics S.A. -- Forecasts and trends, Seagen Inc. -- Forecasts and trends, Biopharmaceutics -- Statistics, Biotechnology industry -- Forecasts and trends -- Statistics, Viral antibodies -- Statistics -- Reports -- Forecasts and trends, Antibodies -- Statistics -- Reports -- Forecasts and trends, Pharmaceutical industry -- Statistics -- Forecasts and trends, Investments -- Statistics, Market trend/market analysis, Banking, finance and accounting industries, Business
Abstract

Dublin, Sep 08, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START EQNX::TICKER_END The 'Global Antibody Drug Conjugates Market Size, Share & Industry Trends Analysis Report By Application, By Technology, By Regional [...]

Published
2022

14. Bladder Cancer Clinical Trial Pipeline Insights Featuring 100+ Companies | DelveInsight

Subjects
ADC Therapeutics S.A. -- Forecasts and trends, Bristol-Myers Squibb Co. -- Forecasts and trends, Pfizer Inc. -- Forecasts and trends, Seagen Inc. -- Forecasts and trends, Business -- Research, BCG vaccines -- Forecasts and trends -- Reports, BCG -- Forecasts and trends -- Reports, Bladder cancer -- Forecasts and trends -- Reports, Cancer -- Care and treatment, Clinical trials -- Forecasts and trends -- Reports, Market trend/market analysis, Business, News, opinion and commentary
Abstract

DelveInsight's bladder cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for bladder cancer treatment. LAS VEGAS, Aug. 23, 2022 /PRNewswire/ -- [...]

Published
2022

15. Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Size to Grow by USD 1.79 billion, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio

Subjects
Merck & Company Inc. -- Forecasts and trends, Spectrum Pharmaceuticals Inc. -- Forecasts and trends, ADC Therapeutics S.A. -- Forecasts and trends, Amgen Inc. -- Forecasts and trends, Bayer AG -- Forecasts and trends, AbbVie Inc. -- Forecasts and trends, Pfizer Inc. -- Forecasts and trends, Novartis AG -- Forecasts and trends, Biotechnology industry -- Forecasts and trends, Non-Hodgkin's lymphomas -- Forecasts and trends -- Reports, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Business, News, opinion and commentary
Abstract

NEW YORK, July 25, 2022 /PRNewswire/ -- DLBCL is a cancer of B-lymphocytes and is the most common type of Non-Hodgkins Lymphoma (NHL) among adults. It is a fast-growing and [...]

Published
2022

16. The Global Antibody Drug Conjugates Market size is expected to reach $13.8 billion by 2028, rising at a market growth of 14.2% CAGR during the forecast period

Subjects
United States. Food and Drug Administration -- Statistics -- Reports, Merck & Company Inc. -- Forecasts and trends, Astellas Pharma Inc. -- Forecasts and trends, Takeda Pharmaceutical Company Ltd. -- Forecasts and trends, ADC Therapeutics S.A. -- Forecasts and trends, GSK PLC -- Forecasts and trends, Pfizer Inc. -- Forecasts and trends, Gilead Sciences Inc. -- Forecasts and trends, Seagen Inc. -- Forecasts and trends, Daiichi Sankyo Company Ltd. -- Forecasts and trends, AstraZeneca PLC -- Forecasts and trends, Biological products industry -- Statistics -- Forecasts and trends, Biopharmaceutics -- Statistics, Biotechnology industry -- Forecasts and trends -- Statistics, Viral antibodies -- Statistics -- Reports -- Forecasts and trends, Chemotherapy -- Forecasts and trends -- Reports -- Statistics, Cancer -- Chemotherapy, Antibodies -- Statistics -- Reports -- Forecasts and trends, Pharmaceutical industry -- Statistics -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries, Business
Abstract

New York, July 07, Jul 07, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START EQNX::TICKER_END Reportlinker.com announces the release of the report 'Global Antibody Drug Conjugates Market Size, Share & Industry [...]

Published
2022

17. The Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market is expected to grow by $ 1.79 bn during 2022-2026 progressing at a CAGR of 7.71% during the forecast period

Subjects
ADC Therapeutics S.A. -- Forecasts and trends, Lymphomas -- Forecasts and trends -- Reports, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries, Business
Abstract

New York, April 18, Apr 18, 2022 (GLOBE NEWSWIRE via COMTEX) -- Reportlinker.com announces the release of the report 'Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2022-2026' - https://www.reportlinker.com/p05589855/?utm_source=GNW [...]

Published
2022

18. Worldwide Antibody Drug Conjugates Industry to Register CAGR of 12.8% during 2021 - 2026

Subjects
Catalent Inc. -- Forecasts and trends, Takeda Pharmaceutical Company Ltd. -- Forecasts and trends, ADC Therapeutics S.A. -- Forecasts and trends, Pfizer Inc. -- Forecasts and trends, AbbVie Inc. -- Forecasts and trends, ImmunoGen Inc. -- Forecasts and trends, AstraZeneca PLC -- Forecasts and trends, Biopharmaceutics -- Forecasts and trends, Viral antibodies -- Forecasts and trends, Antibodies -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

DUBLIN: The report 'Antibody Drug Conjugates Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)' is now offered by ResearchAndMarkets.com. In the report, the antibody-drug conjugates market is [...]

Published
2022

19. The Hodgkin's Lymphoma market size is anticipated to grow during the study period (2018-30) owing to the launch of upcoming therapies such as Tislelizumab, ADCT-301, and others

Subjects
ADC Therapeutics S.A. -- Forecasts and trends, Business -- Research, Non-Hodgkin's lymphomas -- Forecasts and trends -- Reports, Brentuximab vedotin -- Reports -- Forecasts and trends, Epidemiology -- Reports -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-September 17, 2021-: The Hodgkin's Lymphoma market size is anticipated to grow during the study period (2018-30) owing to the launch of upcoming therapies such as Tislelizumab, ADCT-301, and [...]

Published
2021

20. The Diffuse Large B-Cell Lymphoma market outlook is expected to change positively in the upcoming years due to increased global healthcare spending and the proliferation of major players

Subjects
ADC Therapeutics S.A. -- Forecasts and trends, Bristol-Myers Squibb Co. -- Forecasts and trends, Business -- Research, Medical economics -- Forecasts and trends -- Reports, Non-Hodgkin's lymphomas -- Forecasts and trends -- Reports, Brentuximab vedotin -- Reports -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends -- Market size, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-August 26, 2021-: The Diffuse Large B-Cell Lymphoma market outlook is expected to change positively in the upcoming years due to increased global healthcare spending and the proliferation of [...]

Published
2021

21. Relapsed or Refractory Diffuse Large B-cell Lymphoma Markets, 2028

Subjects
ADC Therapeutics S.A. -- Forecasts and trends, Novartis AG -- Forecasts and trends, Lymphomas -- Reports -- Forecasts and trends, Biotechnology industry -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Relapsed or Refractory Diffuse Large B-cell Lymphoma Market - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028' report [...]

Published
2021

22. Relapsed or Refractory Diffuse Large B-cell Lymphoma Markets, 2028 - ResearchAndMarkets.com

Subjects
United States. Food and Drug Administration -- Reports, ADC Therapeutics S.A. -- Forecasts and trends, Novartis AG -- Forecasts and trends, Lymphomas -- Reports -- Forecasts and trends, Biotechnology industry -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Business, Business, international
Abstract

DUBLIN -- The 'Relapsed or Refractory Diffuse Large B-cell Lymphoma Market - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028' report has been added to ResearchAndMarkets.com's offering. Market players [...]

Published
2021

23. Relapsed or Refractory Diffuse Large B-cell Lymphoma Markets, 2028

Subjects
United States. Food and Drug Administration -- Reports, ADC Therapeutics S.A. -- Forecasts and trends, Novartis AG -- Forecasts and trends, Lymphomas -- Reports -- Forecasts and trends, Biotechnology industry -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-May 27, 2021-: Relapsed or Refractory Diffuse Large B-cell Lymphoma Markets, 2028 (C)1994-2021 M2 COMMUNICATIONS RDATE:27052021 The 'Relapsed or Refractory Diffuse Large B-cell Lymphoma Market - Size, Share, Outlook, [...]

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results